Study of NGR-hTNF Administered at High Doses in Patient With Advanced or Metastatic Solid Tumour
Status:
Completed
Trial end date:
2017-02-01
Target enrollment:
Participant gender:
Summary
The main objective of the trial is to document the safety and antivascular effect of
escalating doses of NGR-hTNF, from 60 mcg/sqm to 325 mcg/sqm, in patients affected by
advanced or metastatic solid tumors not amenable of standard therapies.
Safety will be established by clinical and laboratory assessment according to NCI-CTCAE
criteria (version 4.02).